Matrixx announces plans to enter antacid market with Xcid
NEW YORK Matrixx revealed plans to enter the antacid market with a product called Xcid early in 2009 Wednesday, during the Roth Conference Presentation held here. According to the company, the acid neutralizing category is currently measured at around $500 million.
Xcid, featuring “from the makers of Zicam” on the packaging, will contain maximum strength quantities of calcium carbonate and magnesium hydroxide in a liquid format and will be launched with three flavors. Liquid antacids are considered highly efficacious among consumers, Carl Johnson, Matrixx president and chief executive officer, said, but there aren’t many good-flavored products currently on the market.
Matrixx will also be entering the oral care market in 2009, and will potentially target the analgesic sector for future product development.
Bayer announces deal to buy Citracal
MORRISTOWN, N.J. Bayer HealthCare on Thursday announced an agreement with Mission Pharmacal Company to acquire its global Citracal line of over-the-counter calcium supplements.
The companies have not disclosed the financial terms of the transaction, which is expected to close during the fourth quarter of 2007 subject to regulatory approvals.
“Our consumer health businesses are a key component of Bayer HealthCare and we will continue to invest in this area in order to maintain a diversified portfolio,” stated Arthur Higgins, chairman of Bayer HealthCare. “This acquisition further affirms our strategy and commitment to grow our consumer health segments and will help to solidify our number two position in the global OTC market.”
“The Citracal brand offers very attractive growth potential both in the critically important U.S. market and for our nutritionals portfolio, which is a key growth driver for us now and in the future,” stated Gary Balkema, president of Bayer HealthCare’s Consumer Care Division.
Citracal is primarily sold in North America and saw net sales of $47 million for fiscal year 2007.
This acquisition will increase Bayer Consumer Care’s market presence in the United States, which includes leading dietary supplement brands like One-A-Day.
Corgenix announces FDA approval for test to measure effectiveness of Aspirin
DENVER Corgenix Medical Corporation on Monday announced the recent introduction of its AspirinWorks Test Kit to doctors following approval from the Food and Drug Administration.
“We are pleased that AspirinWorks testing is now offered nationally through the LabCorp network of laboratories, making the test available to virtually every physician in the U.S.,” stated Corgenix’ clinical affairs director Gordon Ens.
The new test, which was launched nationwide in June following FDA 510(k) clearance, measures aspirin effectiveness on platelets through direct measurement of thromboxane production (aspirin’s target). The stickier the blood platelets, the less impact the aspirin is having. This information allows physicians to individualize a patient’s therapy.
“In the past few months, we have experienced a rapid increase in public interest for the AspirinWorks test,” stated Douglass Simpson, Corgenix’ president and chief executive officer. “There is growing acceptance among physicians to test for aspirin effectiveness, and we expect that by the end of 2007 a significant number of the most important clinical labs will be routinely running this test.”